Pasithea Therapeutics(KTTA.US)

Last Updated 19:00:00 ET
longbridge loading

Pasithea Therapeutics Appoints Kartik Krishnan As CMO

rttnews·
US
KTTAW
-53.33%
US
KTTA
+3.19%
US
IXJ
-0.08%
rttnews·
US
KTTAW
-53.33%
US
KTTA
+3.19%
US
IXJ
-0.08%

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer | KTTA Stock News

StockTitan·
US
KTTAW
-53.33%
US
KTTA
+3.19%
US
LABU
+6.80%
StockTitan·
US
KTTAW
-53.33%
US
KTTA
+3.19%
US
LABU
+6.80%

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) | KTTA Stock News

StockTitan·
US
KTTAW
-53.33%
US
KTTA
+3.19%
US
FBT
+0.60%
StockTitan·
US
KTTAW
-53.33%
US
KTTA
+3.19%
US
FBT
+0.60%

MindBio Announces Closing of Private Placement

The newswire.ca·
US
NBSE.ESC
0.00%
US
BTMD
+3.80%
US
SBIO
+1.63%
The newswire.ca·
US
NBSE.ESC
0.00%
US
BTMD
+3.80%
US
SBIO
+1.63%

Pasithea Therapeutics | 10-K: FY2025 Revenue: USD 0

Earnings Watch·
US
KTTA
+3.19%
Earnings Watch·
US
KTTA
+3.19%

MindBio Announces Upsize to Private Placement up to $1.5 Million

The newswire.ca·
US
IBBQ
+1.62%
US
FBT
+0.60%
US
BIB
+2.80%
The newswire.ca·
US
IBBQ
+1.62%
US
FBT
+0.60%
US
BIB
+2.80%

MindBio to Raise Up to $650,000 for AI Intoxication Detection Expansion in Mining Sector

Tip Ranks·
US
KTTAW
-53.33%
US
KTTA
+3.19%
US
PBE
0.00%
Tip Ranks·
US
KTTAW
-53.33%
US
KTTA
+3.19%
US
PBE
0.00%
© 2026 Longbridge｜Disclaimer